Article Text
PDFNeurology in practice
Multiple sclerosis
Statistics from Altmetric.com
Footnotes
Competing interests: My department has received funding from Genzyme for clinical trials and experimental work on alemtuzumab as a treatment of multiple sclerosis. I have received travel expenses for speaking at meetings about alemtuzumab.
Linked Articles
- Editor’s choice
Read the full text or download the PDF:
Other content recommended for you
- Imaging in multiple sclerosis
- New MS diagnostic criteria in practice
- CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease
- Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders
- Tumefactive demyelination: an approach to diagnosis and management
- Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes
- Prognostication and contemporary management of clinically isolated syndrome
- Multiple sclerosis: diagnosis and the management of acute relapses
- Spinal cord MRI in clinically isolated optic neuritis
- Predicting and preventing the future: actively managing multiple sclerosis